Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network

Publication

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network

Journal Paper/Review - May 2, 2018

Ludwig Heinz, Cook Gordon, Leleu Xavier, Goldschmidt Hartmut, Jackson Graham, Kaiser Martin, Weisel Katja, van de Donk Niels W C J, Waage Anders, Beksac Meral, Mellqvist Ulf H, Engelhardt Monika, Caers Jo, Driessen Christoph, Bladé Joan, Mateos Maria-Victoria, Garderet Laurent, Delforge Michel, Facon Thierry, Einsele Hermann, Gay Francesca, Moreau Philippe, Avet-Loiseau Hervé, Boccadoro Mario, Hájek Roman, Mohty Mohamad, Cavo Michele, Dimopoulos Meletios A, San-Miguel Jesús F, Terpos Evangelos, Zweegman Sonja, Sonneveld Pieter

Citation

Ludwig H, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk N, Waage A, Beksac M, Mellqvist U, Engelhardt M, Caers J, Driessen C, Bladé J, Mateos M, Garderet L, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hájek R, Mohty M, Cavo M, Dimopoulos M, San-Miguel J, Terpos E, Zweegman S, Sonneveld P. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia 2018

Type

Journal Paper/Review (English)

Journal

Leukemia 2018

Publication Date

May 2, 2018

Issn Electronic

1476-5551

Brief description/objective

During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.